<?xml version="1.0" encoding="UTF-8"?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1" xml:lang="zh" xsi:noNamespaceSchemaLocation="https://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1.xsd"><front><journal-meta><!-- 出版商赋予期刊ID--><journal-id journal-id-type="publisher-id">YIKE</journal-id><journal-title-group><!-- 期刊中文全称--><journal-title>安徽医科大学学报</journal-title><!-- 期刊英文全称--><journal-title xml:lang="en">Acta Universitatis Medicinalis Anhui</journal-title><!-- 期刊英文缩写--><abbrev-journal-title abbrev-type="publisher" xml:lang="en">Acta Universitatis Medicinalis Anhui</abbrev-journal-title><!-- 期刊中文缩写--><abbrev-journal-title abbrev-type="publisher">安徽医科大学学报</abbrev-journal-title></journal-title-group><!-- 期刊ISSN号--><issn pub-type="ppub">1000-1492</issn><!-- 期刊CN号--><issn pub-type="cn">34-1065/R</issn><publisher><!--出版商英文名称【预置实体】 待确认 --><publisher-name xml:lang="en">Anhui Lianzhong Printing Limited Company</publisher-name><!--出版商英文地址【预置实体】 --><publisher-loc xml:lang="en">Editorial Board of Acta Universitatis Medi-cinalis Anhui Meishan Road , Hefei 230032</publisher-loc><!-- 出版商中文名称【预置实体】--><publisher-name>《安徽医科大学学报》编辑部</publisher-name><!--出版商中文地址【预置实体】 --><publisher-loc>安徽省合肥市安徽医科大学校内老图书馆三楼</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1000–1492（2026）06–1124–06</article-id><article-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018</article-id><article-id pub-id-type="manuscript">V301汪琳丽</article-id><article-categories><subj-group subj-group-type="clc"><subject>R 34</subject></subj-group><subj-group subj-group-type="dc"><subject>A</subject></subj-group><subj-group subj-group-type="heading"><subject>临床医学研究</subject></subj-group></article-categories><title-group><article-title><italic>SLC7A11</italic>基因多态性与幽门螺杆菌感染及非贲门胃癌的关联研究</article-title><trans-title-group xml:lang="en"><trans-title>Association study of <italic>SLC7A11</italic> gene polymorphisms with <italic>helicobacter pylori</italic> infection and non-cardia gastric cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name-alternatives><name name-style="eastern"><surname>汪</surname><given-names>琳丽</given-names></name><name name-style="eastern" xml:lang="en"><surname>Wang</surname><given-names>Linli</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="fna1"/><xref ref-type="author-notes" rid="fne1"><sup>*</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name-alternatives><name name-style="eastern"><surname>高</surname><given-names>芳</given-names></name><name name-style="eastern" xml:lang="en"><surname>Gao</surname><given-names>Fang</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="author-notes" rid="fne1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name-alternatives><name name-style="eastern"><surname>董</surname><given-names>文杰</given-names></name><name name-style="eastern" xml:lang="en"><surname>Dong</surname><given-names>Wenjie</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name-alternatives><name name-style="eastern"><surname>褚</surname><given-names>宁</given-names></name><name name-style="eastern" xml:lang="en"><surname>Chu</surname><given-names>Ning</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern"><surname>贾</surname><given-names>彦彬</given-names></name><name name-style="eastern" xml:lang="en"><surname>Jia</surname><given-names>Yanbin</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/><xref ref-type="author-notes" rid="fna2"/></contrib><aff-alternatives id="aff1"><aff><label>1</label><institution>包头医学院，基础医学与法医学院</institution>、，<city>包头</city>  <postal-code>014040</postal-code></aff><aff xml:lang="en"><label>1</label><institution>School of Basic Medicine and Forensic Medicine, Baotou Medical College</institution>， <city>Baotou</city>  <postal-code>014040</postal-code></aff></aff-alternatives><aff-alternatives id="aff2"><aff><label>2</label><institution>包头医学院，医学技术学院</institution>，<city>包头</city>  <postal-code>014040</postal-code></aff><aff xml:lang="en"><label>2</label><institution>School of Medical Technology, Baotou Medical College</institution>， <city>Baotou</city>  <postal-code>014040</postal-code></aff></aff-alternatives></contrib-group><author-notes><corresp xml:lang="en" id="cor1"><named-content content-type="corresp-name">Jia Yanbin</named-content>， E-mail： <email>jyb690318@hotmail.com</email></corresp><fn fn-type="equal" id="fne1"><p>对本文具有同等贡献</p></fn><fn fn-type="other" specific-use="about-author" id="fna1"><p><named-content content-type="corresp-name">汪琳丽</named-content>，女，硕士研究生</p></fn><fn fn-type="other" specific-use="about-author" id="fna2"><p><named-content content-type="corresp-name">贾彦彬</named-content>，女，教授，硕士生导师，通信作者，E-mail： jyb690 <email>318@hotmail.com</email></p></fn></author-notes><pub-date pub-type="epub" iso-8601-date="2026-04-07T17：25：44"><day>07</day><month>04</month><year>2026</year></pub-date><pub-date pub-type="ppub"><day>23</day><month>06</month><year>2026</year></pub-date><volume>61</volume><issue>6</issue><issue-id>17</issue-id><fpage>1124</fpage><lpage>1129</lpage><page-range>1124-1129</page-range>    <history>   <date date-type="accepted"><day>04</day><month>03</month><year>2026</year></date></history>  <abstract abstract-type="key-points"><sec><title>目的</title><p>探讨溶质载体家族7成员11（<italic>SLC7A11</italic>）基因多态性与非贲门胃癌（NCGC）发病风险以及幽门螺杆菌（<italic>H. pylori</italic>）感染的相关性。</p></sec><sec><title>方法</title><p>纳入435例NCGC患者和479例健康体检者。通过聚合酶链式反应<italic>-</italic>限制性片段长度多态性（PCR-RFLP）技术对<italic>SLC7A11</italic>基因上的位点（rs7674870、rs11734488、rs12506138、rs10022036）进行基因分型。统计分析各位点以及各单体型是否影响<italic>H. pylori</italic>感染及NCGC的发生。</p></sec><sec><title>结果</title><p>SNP rs7674870、rs11734488和rs12506138与<italic>H. pylori</italic>感染无显著关联（<italic>P</italic>&gt;0.05）；rs12506138的CT基因型和CC基因型在共显性模型下与TT基因型相比降低了NCGC的发病风险；由<italic>SLC7A11 </italic>rs7674870、rs11734488、rs12506138构建的A-C-C和A-T-C单体型与NCGC发病风险降低相关；A-T-T和G-C-C单体型与NCGC发病风险增加相关。</p></sec><sec><title>结论</title><p><italic>SLC7A11</italic> rs7674870、rs11734488并非<italic>H. pylori</italic>感染和NCGC发病的关键遗传位点。<italic>SLC7A11 </italic>rs12506138可作为NCGC的保护性遗传位点，可拮抗NCGC的发生进程。由上述三个位点构成的单体型可参与调控NCGC的整体遗传易感性。</p></sec></abstract><trans-abstract abstract-type="key-points" xml:lang="en"><sec><title>Objective</title><p>To explore the correlation between the polymorphisms of the solute carrier family7 member11 （<italic>SLC7A11） </italic>gene and the risk of non-cardia gastric cancer （NCGC） as well as the infection of <italic>Helicobacter pylori</italic> （<italic>H.pylori</italic>）.</p></sec><sec><title>Methods</title><p>A total of 435 patients with NCGC and 479 healthy individuals undergoing physical examinations were included. The polymorphisms of the <italic>SLC7A11</italic> gene （rs7674870， rs11734488， rs12506138， rs10022036） were genotyped using the polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） technique. The influence of each locus on <italic>H. pylori</italic> infection and the occurrence of NCGC was analyzed.</p></sec><sec><title>Results</title><p>No significant associations were found among SNP rs7674870， rs11734488， and rs12506138 and <italic>H. pylori</italic> infection （<italic>P</italic>&gt;0.05）. The CT genotype and CC genotype of rs12506138， when in a codominant model， reduced the risk of developing NCGC compared to the TT genotype； the A-C-C and A-T-C haplotypes constructed by <italic>SLC7A11</italic> rs7674870， rs11734488， rs12506138 were associated with a reduced risk of NCGC； the A-T-T and G-C-C haplotypes were associated with an increased risk of NCGC.</p></sec><sec><title>Conclusion</title><p><italic>SLC7A11</italic> rs7674870 and rs11734488 are not pivotal genetic loci for <italic>H. pylori</italic> infection and the pathogenesis of NCGC. <italic>SLC7A11</italic> rs12506138 acts as a protective genetic locus for NCGC and antagonizes its oncogenic progression. The haplotype composed of the above three loci participates in regulating the overall genetic susceptibility to NCGC.</p></sec></trans-abstract><kwd-group kwd-group-type="author"><kwd>溶质载体家族7成员11</kwd><kwd>单核苷酸多态性</kwd><kwd>非贲门胃癌</kwd><kwd>幽门螺杆菌</kwd><kwd>单体型</kwd><kwd>铁死亡</kwd></kwd-group><kwd-group xml:lang="en" kwd-group-type="author"><kwd>solute carrier family 7 member 11</kwd><kwd>single nucleotide polymorphism</kwd><kwd>non-cardia gastric cancer</kwd><kwd><italic>Helicobacter pylori</italic></kwd><kwd>haplotypes</kwd><kwd>ferroptosis</kwd></kwd-group><funding-group><award-group><funding-source>内蒙古自治区自然科学基金项目</funding-source><award-id>2024MS08079</award-id></award-group><award-group><funding-source>包头医学院创新团队发展计划项目</funding-source><award-id>bycxtd-06</award-id></award-group><funding-statement>内蒙古自治区自然科学基金项目（编号：2024MS08079）；包头医学院创新团队发展计划项目（编号：bycxtd-06）</funding-statement></funding-group><funding-group xml:lang="en"><award-group><funding-source>Natural Science Foundation of Inner Mongolia Autonomous Region</funding-source><award-id>2024MS08079</award-id></award-group><award-group><funding-source>Innovation Team Development Plan Project of Baotou Medical College</funding-source><award-id>bycxtd-06</award-id></award-group><funding-statement>Natural Science Foundation of Inner Mongolia Autonomous Region （No. 2024MS08079）； Innovation Team Development Plan Project of Baotou Medical College （No. bycxtd-06）</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="5"/><equation-count count="0"/><ref-count count="10"/><page-count count="6"/><word-count count="16023"/></counts><custom-meta-group><custom-meta><meta-name>version</meta-name><meta-value>1.0.0.25091</meta-value></custom-meta><custom-meta><meta-name>structure-time</meta-name><meta-value>2026-07-29T16:02:46</meta-value></custom-meta><custom-meta><meta-name>word-source</meta-name><meta-value>FX</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>胃癌是最常见的恶性肿瘤之一，其中非贲门胃癌（non-cardia gastric cancer， NCGC）占胃癌总数的70%~80%，其发病机制与慢性炎症及氧化应激密切相关<sup>［<xref ref-type="bibr" rid="R1">1</xref>］</sup>。铁死亡是由脂质过氧化引起的独特细胞死亡方式<sup>［<xref ref-type="bibr" rid="R2">2</xref>］</sup>，通过脂质过氧化物积累和抗氧化系统，如谷胱甘肽过氧化物酶4/溶质载体家族7成员11/还原型谷胱甘肽（glutathione peroxidase 4/solute carrier family 7 member 11/reduced glutathione，GPX4/SLC 7A11/GSH）轴失衡诱导细胞死亡，在胃癌发生及进展中发挥关键作用。</p><p>SLC7A11是胱氨酸/谷氨酸反向转运体的关键亚基，摄取细胞外胱氨酸并释放细胞内谷氨酸<sup>［<xref ref-type="bibr" rid="R3">3</xref>］</sup>，是抗氧化系统的主要组成成分。其功能直接影响细胞内GSH的合成。GSH是机体最重要的抗氧化剂之一，通过清除活性氧维持氧化还原稳态。近年来研究<sup>［<xref ref-type="bibr" rid="R4">4</xref>］</sup>表明，SLC7A11在多种肿瘤中异常高表达，促进GSH合成，增强肿瘤细胞的抗氧化能力，抑制肿瘤细胞的铁死亡并引起肿瘤的发生。然而，<italic>SLC7A11</italic>的单核苷酸多态性（single nucleotide polymorphism，SNP）是否影响NCGC的发病风险还未见报道。该研究基于病例<italic>-</italic>对照设计，探讨<italic>SLC7A11</italic>上的SNP与幽门螺杆菌（<italic>Helicobacter pylori， H. pylori</italic>）感染风险及NCGC发病风险的关联，为NCGC的遗传易感性研究提供新线索。</p><sec id="s1"><label>1</label><title>材料与方法</title><sec id="s1a"><label>1.1</label><title>研究对象</title><p specific-use="noneIndent">按照研究<sup>［<xref ref-type="bibr" rid="R5">5</xref>］</sup>方法收集样本。病例组为2015—2024年间于包头市肿瘤医院确诊的原发性NCGC患者，共435例，其中男性326例，女性109例。年龄在25~89岁之间，且未经放射治疗或化学药物治疗。对照组为同时间包头医学院第一附属医院及第二附属医院健康体检人群，共479例，其中男性335例，女性144例。所有对照均无恶性肿瘤病史、明显的消化系统病史和遗传病史，且与病例组在年龄（±5岁）、性别上匹配。所有研究对象均为汉族，且签署了知情同意书，研究经包头医学院伦理委员会批准（批件号：包医伦审［2024］8号）。</p></sec><sec id="s1b"><label>1.2</label><title>实验方法</title><sec id="s1b1"><label>1.2.1</label><title><italic>H. pylori</italic>检测</title><p specific-use="noneIndent">本研究采用<sup>14</sup>C尿素呼气试验和人<italic>H. pylori </italic>IgG抗体ELISA试剂盒在正常对照中检测<italic>H. pylori</italic>感染，<sup>14</sup>C尿素呼气试剂盒购自深圳市中核海得威生物科技有限公司，ELISA试剂盒购自泉州市睿信生物科技有限公司，所有操作及结果判断均严格按照试剂盒说明书进行，任意检测结果为阳性均判定为阳性样本<sup>［<xref ref-type="bibr" rid="R6">6</xref>］</sup>。</p></sec><sec id="s1b2"><label>1.2.2</label><title>SNP筛选</title><p specific-use="noneIndent">在NCBI数据库（<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/">https：//www.ncbi.nlm.nih.gov/</ext-link>）选取满足以下两点的位点：① 位于5′调控区、5′UTR区、3′UTR区、3′调控区、外显子区域或文献报道可能与疾病关联；② 最小等位基因频率（minor allele frequency， MAF）≥0.05。筛选得到SNP位点rs7674870、rs11734488、rs12506138、rs10022036，这些SNP在<italic>SLC7A11</italic>基因中位置见<xref ref-type="fig" rid="F1">图1</xref>。</p><fig position="float" id="F1"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.F001</object-id><label>图1</label><caption><title>各SNP在<italic>SLC7A11</italic>基因中的位置</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.1</label><title>The position of each SNP in <italic>SLC7A11</italic> gene</title></abstract><alternatives><graphic specific-use="print" xlink:href="media/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F001.eps" id="Graphic1"><?fx-imagestate width="70.55554962" height="23.98888779"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F001.jpg"><?fx-imagestate width="70.55554962" height="23.98888779"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F001c.jpg"><?fx-imagestate width="70.55554962" height="23.98888779"?></graphic></alternatives></fig></sec><sec id="s1b3"><label>1.2.3</label><title>基因分型</title><p specific-use="noneIndent">提取研究样本的全血基因组DNA后，首先在Primer 3在线软件上设计引物扩增目标DNA片段，经PCR扩增（PCR反应条件均为：94 ℃预变性5 min；94 ℃变性30 s，在各位点退火温度退火30 s，72 ℃延伸50 s，共循环29次；最后72 ℃延伸5 min）后，得到各位点的PCR产物，用相应的限制性内切酶消化产物1 h。酶切完成后，所得产物通过2%琼脂糖凝胶电泳后于凝胶成像仪中曝光，分析片段大小差异以判定基因型。各SNP位点的基因分型概况见<xref ref-type="table" rid="T1">表1</xref>，PCR反应电泳图见<xref ref-type="fig" rid="F2">图2</xref>，酶切反应电泳图见<xref ref-type="fig" rid="F3">图3</xref>。</p><table-wrap id="T1"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.T001</object-id><label>表1</label><caption><p>各SNP位点的基因分型概况</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.1</label><title>The overview of genotyping at each SNP locus</title></abstract><alternatives><table id="Table1"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">SNP</th><th align="center" style="border-top:solid;border-bottom:solid;">Primer sequence （5′-3′）</th><th align="center" style="border-top:solid;border-bottom:solid;">Annealing temperature （℃）</th><th align="center" style="border-top:solid;border-bottom:solid;">PCR length （bp）</th><th align="center" style="border-top:solid;border-bottom:solid;">Restriction enzyme</th><th align="center" style="border-top:solid;border-bottom:solid;">Digestion temperature （℃）</th><th align="center" style="border-top:solid;border-bottom:solid;">Length of fragment after digestion （bp）</th></tr></thead><tbody><tr align="center"><td align="left">rs7674870</td><td align="left" style="text-indent:1em;"><p>F：CAGGACCTCGAATGGAACA</p><p>R：TCTTGATTTGCAGATGAATATACTG</p></td><td align="center">59</td><td align="center">291</td><td align="center">Hpy188Ⅰ</td><td align="center">37</td><td align="center"><p>AA：110/181</p><p>AG：110/181/291</p></td></tr><tr align="center"><td align="left">rs11734488</td><td align="left" style="text-indent:1em;"><p>F：TCATGGCAAAATTTCTTAACATT</p><p>R：TCCATGATCTCAATTGACTACACTT</p></td><td align="center">60</td><td align="center">213</td><td align="center">SmlⅠ</td><td align="center">55</td><td align="center"><p>TT：82/131</p><p>CT：82/131/213</p></td></tr><tr align="center"><td align="left">rs12506138</td><td align="left" style="text-indent:1em;"><p>F：TCTCTAGGGTAGAATGTTTACAGGAG</p><p>R：TCAGTCATGTGGTTGTGCTG</p></td><td align="center">58</td><td align="center">245</td><td align="center">Tsp45Ⅰ</td><td align="center">65</td><td align="center"><p>CC：84/161</p><p>CT：84/161/245</p></td></tr><tr align="center"><td align="left" style="border-bottom:solid;">rs10022036</td><td align="left" style="border-bottom:solid;text-indent:1em;"><p>F：GGTGGTTTTGATTTGCATTTCT</p><p>R：ACTGTTAACAAACAGACAACCTACA</p></td><td align="center" style="border-bottom:solid;">59</td><td align="center" style="border-bottom:solid;">250</td><td align="center" style="border-bottom:solid;">Tsp45Ⅰ</td><td align="center" style="border-bottom:solid;">65</td><td align="center" style="border-bottom:solid;"><p>AA：96/154</p><p>AT：96/154/250</p></td></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T001.jpg"><?fx-imagestate width="169.79998779" height="39.79998016"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T001c.jpg"><?fx-imagestate width="169.79998779" height="39.79998016"?></graphic></alternatives></table-wrap><fig position="float" id="F2"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.F002</object-id><label>图2</label><caption><title><italic>SLC7A11</italic>基因SNP rs7674870、rs11734488、rs12506138 PCR产物电泳图</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.2</label><title>Electrophoresis gel images of PCR products of <italic>SLC7A11</italic> gene SNP rs7674870， rs11734488， and rs12506138</title></abstract><abstract abstract-type="note"><p>A： Electrophoresis gel image of PCR products of SNP rs7674870； B： Electrophoresis gel image of PCR products of rs11734488； C： Electrophoresis gel image of PCR products of rs12506138； M： 50 bp Ladder； A1-A6： PCR product of SNP rs7674870； B1-B6： PCR product of SNP rs11734488； C1-C6： PCR product of SNP rs12506138； A7， B7 and C7： Negative control.</p></abstract><alternatives><graphic specific-use="print" xlink:href="media/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F002.eps" id="Graphic2"><?fx-imagestate width="157.69168091" height="29.98611259"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F002.jpg"><?fx-imagestate width="157.69168091" height="29.98611259"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F002c.jpg"><?fx-imagestate width="157.69168091" height="29.98611259"?></graphic></alternatives></fig><fig position="float" id="F3"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.F003</object-id><label>图3</label><caption><title><italic>SLC7A11</italic>基因SNP rs7674870、rs11734488、rs12506138酶切产物电泳图</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.3</label><title>Electrophoresis gel images of digestion products of <italic>SLC7A11</italic> gene SNPs rs7674870， rs11734488， and rs12506138</title></abstract><abstract abstract-type="note"><p>A： Electrophoresis gel image of digestion products of SNPs rs7674870； B： Electrophoresis gel image of digestion products of SNPs rs11734488； C： Electrophoresis gel image of digestion products of SNPs rs12506138； M： 50 bp Ladder； A1： PCR product of SNP rs7674870； A2-A3， A4-A5， A6-A7： SNP rs7674870 TT， AA， AT genotypes； B1： PCR product of SNP rs11734488； B2-B3， B4-B5， B6-B7： SNP rs11734488 CC， TT， CT genotypes； C1-C2， C3-C4， C5-C6： SNP rs12506138 TT， CC， CT genotypes； C7： PCR product of SNP rs12506138.</p></abstract><alternatives><graphic specific-use="print" xlink:href="media/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F003.eps" id="Graphic3"><?fx-imagestate width="159.10276794" height="27.51666832"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F003.jpg"><?fx-imagestate width="159.10276794" height="27.51666832"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-F003c.jpg"><?fx-imagestate width="159.10276794" height="27.51666832"?></graphic></alternatives></fig></sec></sec><sec id="s1c"><label>1.3</label><title>统计学处理</title><p specific-use="noneIndent">在SPSS 27.0软件中使用卡方检验比较病例组与对照组的性别分布差异并且对基因型分布进行Hardy Weinberg平衡检验；使用独立样本<italic>t</italic>检验比较病例组和对照组的年龄差异；通过非条件Logistic回归评估各SNP与<italic>H. pylori</italic>感染以及NCGC发病风险的关联性；计算赤池信息准则（akaike information criterion，AIC）以及贝叶斯信息准则（bayesian information criterion，BIC），以最小值作为最佳遗传模型。用SHEsis软件构建单体型，以频率最高的单体型为参照组，分析各单体型与<italic>H. pylori</italic>感染以及NCGC发病风险的关联性。</p></sec></sec><sec id="s2"><label>2</label><title>结果</title><sec id="s2a"><label>2.1</label><title>SNP与<italic>H. pylori</italic>感染风险的关系</title><sec id="s2a1"><label>2.1.1</label><title>正常对照的一般情况</title><p specific-use="noneIndent">477例正常对照中，184例为<italic>H. pylori</italic>阳性组（男性123例，女性61例，平均年龄为64.34±8.91岁），293例为<italic>H. pylori</italic>阴性组（男性210例，女性83例，平均年龄为61.52±11.67岁），阳性组与阴性组年龄分布（<italic>χ<sup>2</sup></italic>=1.248，<italic>P=</italic>0.264）、性别分布（<italic>t</italic>=2.808，<italic>P=</italic>0.052）均无差异。</p></sec><sec id="s2a2"><label>2.1.2</label><title><italic>SLC7A11</italic>各SNP与<italic>H. pylori</italic>感染的关系</title><p>rs7674870、rs11734488、rs12506138在<italic>H. pylori</italic>感染阴性组的基因型分布符合Hardy Weinberg平衡。rs7674870、rs11734488、rs12506138与<italic>H. pylori</italic>感染风险无显著关联（均<italic>P</italic>&gt;0.05）。见<xref ref-type="table" rid="T2">表2</xref>。由于rs10022036在正常对照组中A等位基因为0，且仅在病例组中出现5例，因此在后续的分析中去掉了该位点。</p><table-wrap id="T2"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.T002</object-id><label>表2</label><caption><p>各SNP与<italic>H. pylori</italic>感染风险的关联分析 ［<italic>n</italic>（%）］</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.2</label><title>Association analysis between each SNP and the risk of <italic>H. pylori</italic> infection ［<italic>n</italic>（%）］</title></abstract><alternatives><table id="Table2"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">SNP</th><th align="center" style="border-top:solid;border-bottom:solid;">Genetic model</th><th align="center" style="border-top:solid;border-bottom:solid;">Genotype</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>H. pylori</italic><sup>-</sup></th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>H. pylori<sup>+</sup></italic></th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>OR </italic>（95%<italic>CI</italic>）</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>P </italic>value</th><th align="center" style="border-top:solid;border-bottom:solid;">AIC</th><th align="center" style="border-top:solid;border-bottom:solid;">BIC</th></tr></thead><tbody><tr align="center"><td align="left">rs7674870</td><td align="left" style="text-indent:1em;">Codominant</td><td align="center">AA</td><td align="center">122 （41.7）</td><td align="center">78 （42.4）</td><td align="center">1</td><td align="left"/><td align="center">638.06</td><td align="center">654.75</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">AG</td><td align="center">131 （44.8）</td><td align="center">85 （46.2）</td><td align="center">1.00 （0.671-1.488）</td><td align="center">0.998</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">GG</td><td align="center">40 （13.5）</td><td align="center">21 （11.4）</td><td align="center">0.79 （0.430-1.450）</td><td align="center">0.446</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Dominant</td><td align="center">AA</td><td align="center">122 （41.7）</td><td align="center">78 （42.4）</td><td align="center">1</td><td align="left"/><td align="center">638.30</td><td align="center">654.99</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">AG+GG</td><td align="center">171 （58.3）</td><td align="center">106 （57.6）</td><td align="center">0.95 （0.651-1.387）</td><td align="center">0.792</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Recessive</td><td align="center">AA+AG</td><td align="center">253 （86.5）</td><td align="center">163 （88.6）</td><td align="center">1</td><td align="left"/><td align="center">637.67</td><td align="center">654.36</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">GG</td><td align="center">40 （13.5）</td><td align="center">21 （11.4）</td><td align="center">0.79 （0.446-1.397）</td><td align="center">0.417</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Overdominant</td><td align="center">AA+GG</td><td align="center">162 （55.2）</td><td align="center">99 （53.8）</td><td align="center">1</td><td align="left"/><td align="center">638.19</td><td align="center">654.88</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">AG</td><td align="center">131 （44.8）</td><td align="center">85 （46.2）</td><td align="center">1.06 （0.726-1.533）</td><td align="center">0.777</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left">rs11734488</td><td align="left" style="text-indent:1em;">Codominant</td><td align="center">TT</td><td align="center">214 （73.1）</td><td align="center">143 （77.7）</td><td align="center">1</td><td align="left"/><td align="center">638.21</td><td align="center">654.89</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT</td><td align="center">71 （24.2）</td><td align="center">32 （17.4）</td><td align="center">0.71 （0.440-1.132）</td><td align="center">0.148</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">8 （2.7）</td><td align="center">9 （4.9）</td><td align="center">1.71 （0.633-4.596）</td><td align="center">0.291</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Dominant</td><td align="center">TT</td><td align="center">214 （73.1）</td><td align="center">143（77.7）</td><td align="center">1</td><td align="left"/><td align="center">637.42</td><td align="center">654.10</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT+CC</td><td align="center">79 （26.9）</td><td align="center">41（22.3）</td><td align="center">0.81 （0.521-1.251）</td><td align="center">0.338</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Recessive</td><td align="center">TT+CT</td><td align="center">285 （97.3）</td><td align="center">175（95.1）</td><td align="center">1</td><td align="left"/><td align="center">636.85</td><td align="center">653.54</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">8 （2.7）</td><td align="center">9（4.9）</td><td align="center">1.84 （0.687-4.942）</td><td align="center">0.225</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Overdominant</td><td align="center">TT+CC</td><td align="center">222 （75.8）</td><td align="center">152 （82.6）</td><td align="center">1</td><td align="left"/><td align="center">635.85</td><td align="center">652.54</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT</td><td align="center">71 （24.2）</td><td align="center">32 （17.4）</td><td align="center">0.69 （0.430-1.101）</td><td align="center">0.119</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left">rs12506138</td><td align="left" style="text-indent:1em;">Codominant</td><td align="center">TT</td><td align="center">95 （32.4）</td><td align="center">57 （31.0）</td><td align="center">1</td><td align="left"/><td align="center">638.15</td><td align="center">654.84</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT</td><td align="center">150 （51.2）</td><td align="center">94 （51.1）</td><td align="center">1.07 （0.699-1.625）</td><td align="center">0.768</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">48 （16.4）</td><td align="center">33 （17.9）</td><td align="center">1.12 （0.642-1.968）</td><td align="center">0.682</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Dominant</td><td align="center">TT</td><td align="center">95 （32.4）</td><td align="center">57 （31.0）</td><td align="center">1</td><td align="left"/><td align="center">638.19</td><td align="center">654.88</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT+CC</td><td align="center">198 （67.6）</td><td align="center">137 （69.0）</td><td align="center">1.08 （0.724-1.612）</td><td align="center">0.706</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Recessive</td><td align="center">TT+CT</td><td align="center">245 （83.6）</td><td align="center">151 （82.1）</td><td align="center">1</td><td align="left"/><td align="center">638.23</td><td align="center">654.92</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">48 （16.4）</td><td align="center">33 （17.9）</td><td align="center">1.08 （0.658-1.778）</td><td align="center">0.758</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Overdominant</td><td align="center">TT+CC</td><td align="center">143 （48.8）</td><td align="center">90 （48.9）</td><td align="center">1</td><td align="left"/><td align="center">638.32</td><td align="center">655.00</td></tr><tr align="center"><td align="left" style="border-bottom:solid;"/><td align="left" style="border-bottom:solid;"/><td align="center" style="border-bottom:solid;">CT</td><td align="center" style="border-bottom:solid;">150 （51.2）</td><td align="center" style="border-bottom:solid;">94 （51.1）</td><td align="center" style="border-bottom:solid;">1.02 （0.704-1.489）</td><td align="center" style="border-bottom:solid;">0.902</td><td align="left" style="border-bottom:solid;"/><td align="left" style="border-bottom:solid;"/></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T002.jpg"><?fx-imagestate width="169.79997253" height="126.00001526"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T002c.jpg"><?fx-imagestate width="169.79997253" height="126.00001526"?></graphic></alternatives></table-wrap></sec><sec id="s2a3"><label>2.1.3</label><title><italic>SLC7A11</italic>单体型与<italic>H. pylori</italic>感染的关系</title><p>rs7674870、rs11734488、rs12506138共构建出6种单体型（频率小于0.03不计入统计）：A-C-C、A-C-T、A-T-C、A-T-T、G-T-C、G-T-T。经分析显示均与<italic>H. pylori</italic>易感性不相关（<italic>P</italic>&gt;0.05）。见<xref ref-type="table" rid="T3">表3</xref>。</p><table-wrap id="T3"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.T003</object-id><label>表3</label><caption><p>单体型与<italic>H. pylori</italic>感染风险关系 ［<italic>n</italic>（%）］</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.3</label><title>The relationships between haplotypes and the risk of <italic>H. pylori</italic> infection ［<italic>n</italic>（%）］</title></abstract><alternatives><table id="Table3"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">Haplotype</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>H. pylori<sup>+</sup></italic></th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>H. pylori</italic><sup>-</sup></th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>OR </italic>（95%<italic> CI</italic>）</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>P </italic>value</th></tr></thead><tbody><tr align="center"><td align="left">A-C-C</td><td align="center">19.52 （5.3）</td><td align="center">30.49 （5.2）</td><td align="center">1.00 （0.556-1.790）</td><td align="center">0.994</td></tr><tr align="center"><td align="left">A-C-T</td><td align="center">19.50 （5.3）</td><td align="center">26.92 （4.6）</td><td align="center">1.14 （0.625-2.068）</td><td align="center">0.675</td></tr><tr align="center"><td align="left">A-T-C</td><td align="center">80.45 （21.9）</td><td align="center">130.07 （22.2）</td><td align="center">0.95 （0.695-1.308）</td><td align="center">0.768</td></tr><tr align="center"><td align="left">A-T-T</td><td align="center">121.53 （33.0）</td><td align="center">187.53 （32.0）</td><td align="center">1.02 （0.767-1.344）</td><td align="center">0.916</td></tr><tr align="center"><td align="left">G-T-C</td><td align="center">54.17 （14.7）</td><td align="center">72.68 （12.4）</td><td align="center">1.19 （0.814-1.741）</td><td align="center">0.368</td></tr><tr align="center"><td align="left" style="border-bottom:solid;">G-T-T</td><td align="center" style="border-bottom:solid;">61.85 （16.8）</td><td align="center" style="border-bottom:solid;">108.72 （18.6）</td><td align="center" style="border-bottom:solid;">0.86 （0.611-1.218）</td><td align="center" style="border-bottom:solid;">0.402</td></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T003.jpg"><?fx-imagestate width="169.79997253" height="32.15800476"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T003c.jpg"><?fx-imagestate width="169.79997253" height="32.15800476"?></graphic></alternatives></table-wrap></sec></sec><sec id="s2b"><label>2.2</label><title>SNP与NCGC发病风险的关系</title><sec id="s2b1"><label>2.2.1</label><title>病例、对照一般情况的比较</title><p specific-use="noneIndent">在914例研究样本中，435例为NCGC病例（男性326例，女性109例，平均年龄为61.84±10.61岁），479例为正常对照（男性355例，女性144例，平均年龄为62.74±10.94岁），病例组与对照组年龄分布（<italic>χ<sup>2</sup></italic>=2.853，<italic>P=</italic>0.091）、性别分布（<italic>t</italic>=1.254，<italic>P=</italic>0.210）均无差异。</p></sec><sec id="s2b2"><label>2.2.2</label><title><italic>SLC7A11</italic>各SNP与NCGC发病风险的关系</title><p>rs7674870、rs11734488、rs12506138在正常对照组的基因型分布符合Hardy Weinberg平衡。<italic>SLC7A11</italic> rs12506138在共显性、显性、隐性模型下均与NCGC相关联，因在共显性模型下AIC和BIC的数值最小，可视共显性模型为最佳遗传模型。CT和CC基因型相比于TT基因型降低了NCGC发病风险。<italic>SLC7A11 </italic>rs7674870、rs11734488与NCGC发病风险无相关性（<italic>P</italic>&gt;0.05）。见<xref ref-type="table" rid="T4">表4</xref>。</p><table-wrap id="T4"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.T004</object-id><label>表4</label><caption><p>各SNP与NCGC发病风险的关联分析 ［<italic>n</italic>（%）］</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.4</label><title>Association analysis between each SNP and the risk of NCGC ［<italic>n</italic>（%）］</title></abstract><alternatives><table id="Table4"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">SNP</th><th align="center" style="border-top:solid;border-bottom:solid;">Genetic model</th><th align="center" style="border-top:solid;border-bottom:solid;">Genotype</th><th align="center" style="border-top:solid;border-bottom:solid;">Control group</th><th align="center" style="border-top:solid;border-bottom:solid;">Case group</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>OR </italic>（95％<italic>CI</italic>）</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>P </italic>value</th><th align="center" style="border-top:solid;border-bottom:solid;">AIC</th><th align="center" style="border-top:solid;border-bottom:solid;">BIC</th></tr></thead><tbody><tr align="center"><td align="left">rs7674870</td><td align="left" style="text-indent:1em;">Codominant</td><td align="center">AA</td><td align="center">201 （41.9）</td><td align="center">182 （41.8）</td><td align="center">1</td><td align="left"/><td align="center">1 268.40</td><td align="center">1 287.67</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">AG</td><td align="center">217 （45.3）</td><td align="center">193 （44.3）</td><td align="center">0.98 （0.743-1.300）</td><td align="center">0.902</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">GG</td><td align="center">61 （12.7）</td><td align="center">60 （13.8）</td><td align="center">1.08 （0.717-1.629）</td><td align="center">0.709</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Dominant</td><td align="center">AA</td><td align="center">201 （41.9）</td><td align="center">182 （41.8）</td><td align="center">1</td><td align="left"/><td align="center">1 268.46</td><td align="center">1 287.73</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">AG+GG</td><td align="center">278 （58.0）</td><td align="center">253 （58.1）</td><td align="center">1.00 （0.771-1.308）</td><td align="center">0.975</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Recessive</td><td align="center">AA+AG</td><td align="center">418 （87.2）</td><td align="center">375 （86.1）</td><td align="center">1</td><td align="left"/><td align="center">1 268.26</td><td align="center">1 287.53</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">GG</td><td align="center">61 （12.7）</td><td align="center">60 （13.8）</td><td align="center">1.09 （0.743-1.601）</td><td align="center">0.656</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Overdominant</td><td align="center">AA+GG</td><td align="center">262 （54.6）</td><td align="center">242 （55.6）</td><td align="center">1</td><td align="left"/><td align="center">1 268.39</td><td align="center">1 287.66</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">AG</td><td align="center">217 （45.3）</td><td align="center">193 （44.3）</td><td align="center">0.96 （0.742-1.253）</td><td align="center">0.786</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left">rs11734488</td><td align="left" style="text-indent:1em;">Codominant</td><td align="center">TT</td><td align="center">359 （74.9）</td><td align="center">335 （77.0）</td><td align="center">1</td><td align="left"/><td align="center">1 267.91</td><td align="center">1 287.18</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT</td><td align="center">103 （21.5）</td><td align="center">84 （19.3）</td><td align="center">0.85 （0.610-1.173）</td><td align="center">0.316</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">17 （3.5）</td><td align="center">16 （3.7）</td><td align="center">0.98 （0.487-1.979）</td><td align="center">0.957</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Dominant</td><td align="center">TT</td><td align="center">359 （74.9）</td><td align="center">335 （77.0）</td><td align="center">1</td><td align="left"/><td align="center">1 267.60</td><td align="center">1 286.87</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT+CC</td><td align="center">120 （25.0）</td><td align="center">100 （23.0）</td><td align="center">0.87 （0.637-1.176）</td><td align="center">0.355</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Recessive</td><td align="center">TT+CT</td><td align="center">462 （96.4）</td><td align="center">419 （96.3）</td><td align="center">1</td><td align="left"/><td align="center">1 268.46</td><td align="center">1 287.73</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">17 （3.5）</td><td align="center">16 （3.7）</td><td align="center">1.02 （0.506-2.044）</td><td align="center">0.962</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Overdominant</td><td align="center">TT+CC</td><td align="center">372 （78.4）</td><td align="center">351 （80.7）</td><td align="center">1</td><td align="left"/><td align="center">1 267.45</td><td align="center">1 286.73</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT</td><td align="center">103 （21.5）</td><td align="center">84 （19.3）</td><td align="center">0.85 （0.612-1.172）</td><td align="center">0.316</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left">rs12506138</td><td align="left" style="text-indent:1em;">Codominant</td><td align="center">TT</td><td align="center">152 （31.7）</td><td align="center">174 （40.0）</td><td align="center">1</td><td align="left"/><td align="center">1 259.23</td><td align="center">1 278.50</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT</td><td align="center">246 （51.4）</td><td align="center">210 （48.3）</td><td align="center">0.75 （0.563-0.998）</td><td align="center">0.048</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">81 （16.9）</td><td align="center">51 （11.7）</td><td align="center">0.54 （0.359-0.822）</td><td align="center">0.004</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Dominant</td><td align="center">TT</td><td align="center">152 （31.7）</td><td align="center">174 （40.0）</td><td align="center">1</td><td align="left"/><td align="center">1 261.77</td><td align="center">1 281.04</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CT+CC</td><td align="center">327 （68.3）</td><td align="center">261 （60.0）</td><td align="center">0.70 （0.532-0.917）</td><td align="center">0.010</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Recessive</td><td align="center">TT+CT</td><td align="center">398 （83.1）</td><td align="center">384 （98.3）</td><td align="center">1</td><td align="left"/><td align="center">1 263.13</td><td align="center">1 282.40</td></tr><tr align="center"><td align="left"/><td align="left"/><td align="center">CC</td><td align="center">81 （16.9）</td><td align="center">51 （11.7）</td><td align="center">0.64 （0.439-0.939）</td><td align="center">0.022</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left"/><td align="left" style="text-indent:1em;">Overdominant</td><td align="center">TT+CC</td><td align="center">233 （48.6）</td><td align="center">225 （51.7）</td><td align="center">1</td><td align="left"/><td align="center">1 267.71</td><td align="center">1 286.98</td></tr><tr align="center"><td align="left" style="border-bottom:solid;"/><td align="left" style="border-bottom:solid;"/><td align="center" style="border-bottom:solid;">CT</td><td align="center" style="border-bottom:solid;">246 （51.4）</td><td align="center" style="border-bottom:solid;">210 （48.3）</td><td align="center" style="border-bottom:solid;">0.89 （0.687-1.156）</td><td align="center" style="border-bottom:solid;">0.386</td><td align="left" style="border-bottom:solid;"/><td align="left" style="border-bottom:solid;"/></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T004.jpg"><?fx-imagestate width="169.79997253" height="128.79998779"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T004c.jpg"><?fx-imagestate width="169.79997253" height="128.79998779"?></graphic></alternatives></table-wrap></sec><sec id="s2b3"><label>2.2.3</label><title><italic>SLC7A11</italic>单体型与NCGC发病风险的关系</title><p><italic>SLC7A11 </italic>rs7674870、rs11734488、rs12506138三个位点共构建7种单体型（频率小于0.03不计入统计）：A-C-C、A-C-T、A-T-C、A-T-T、G-C-C、G-T-C、G-T-T。以SHEsis 软件默认的最常见单体型为参照，其中A-C-C单体型和A-T-C单体型与NCGC发病风险降低相关；A-T-T单体型和G-C-C单体型与NCGC发病风险增加相关。见<xref ref-type="table" rid="T5">表5</xref>。</p><table-wrap id="T5"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.06.018.T005</object-id><label>表5</label><caption><p>单体型与NCGC发病风险关系 ［<italic>n</italic>（%）］</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.5</label><title>The relationships between haplotypes and the risk of NCGC ［<italic>n</italic>（%）］</title></abstract><alternatives><table id="Table5"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">Haplotype</th><th align="center" style="border-top:solid;border-bottom:solid;">Case group</th><th align="center" style="border-top:solid;border-bottom:solid;">Control group</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>OR </italic>（95% <italic>CI</italic>）</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>P </italic>value</th></tr></thead><tbody><tr align="center"><td align="left">A-C-C</td><td align="center">19.76 （2.3）</td><td align="center">50.83 （5.3）</td><td align="center">0.42 （0.246-0.707）</td><td align="center">&lt;0.001</td></tr><tr align="center"><td align="left">A-C-T</td><td align="center">42.99 （4.9）</td><td align="center">46.17 （1.8）</td><td align="center">1.03 （0.674-1.581）</td><td align="center">0.883</td></tr><tr align="center"><td align="left">A-T-C</td><td align="center">157.98 （18.2）</td><td align="center">211.39（ 22.1）</td><td align="center">0.79 （0.625-0.992）</td><td align="center">0.043</td></tr><tr align="center"><td align="left">A-T-T</td><td align="center">336.27 （38.7）</td><td align="center">310.62 （32.4）</td><td align="center">1.33 （1.096-1.614）</td><td align="center">0.004</td></tr><tr align="center"><td align="left">G-C-C</td><td align="center">28.47 （3.3）</td><td align="center">17.67 （1.8）</td><td align="center">1.81 （0.993-3.303）</td><td align="center">0.050</td></tr><tr align="center"><td align="left">G-T-C</td><td align="center">105.79 （12.2）</td><td align="center">128.11 （13.4）</td><td align="center">0.90 （0.684-1.189）</td><td align="center">0.463</td></tr><tr align="center"><td align="left" style="border-bottom:solid;">G-T-T</td><td align="center" style="border-bottom:solid;">153.95 （17.7）</td><td align="center" style="border-bottom:solid;">170.88 （17.8）</td><td align="center" style="border-bottom:solid;">1.00 （0.783-1.268）</td><td align="center" style="border-bottom:solid;">0.979</td></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T005.jpg"><?fx-imagestate width="169.79998779" height="36.75200653"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/CB7E78C2-414B-4d80-95FF-A2DA1F82BDD5-T005c.jpg"><?fx-imagestate width="169.79998779" height="36.75200653"?></graphic></alternatives></table-wrap></sec></sec></sec><sec id="s3"><label>3</label><title>讨论</title><p>根据解剖学分类，胃癌可分为贲门癌和NCGC。目前，NCGC是胃癌防控的核心主体，其与贲门胃癌有本质差异，其高发与<italic>H. pylori</italic>感染、高盐饮食等可干预危险因素强相关，而贲门胃癌的主要风险为胃食管反流病、肥胖等，两者病因机制截然不同。NCGC的早期症状虽非特异但更易通过针对性筛查发现，当前却面临早期诊断率低、精准治疗靶点适配不足等困境。提高NCGC患者发病早期的检出率可以极大地提高患者生活质量、降低病死率。因此，筛选一些能用于NCGC癌变易感人群筛查的遗传标志物是非常必要的。</p><p><italic>H. pylori</italic>是NCGC发病的始动因子，约90%的NCGC与<italic>H. pylori</italic>感染相关，感染者的胃癌风险是未感染者的3~12倍<sup>［<xref ref-type="bibr" rid="R7">7</xref>］</sup>。但是感染<italic>H. pylori</italic>后不同人的结局大不一样，约80%的患者没有明显症状，但有些患者胃黏膜发生持续炎症。炎症因子诱导细胞氧化应激、脂质过氧化和DNA损伤，导致不同的感染者经历慢性胃炎、萎缩性胃炎、肠组织转化、异型增生、癌变等病变过程的不同阶段<sup>［<xref ref-type="bibr" rid="R8">8</xref>］</sup>，提示个体的遗传因素在胃癌癌变的过程中起到了一定作用。</p><p>SLC7A11位于细胞膜上，是胱氨酸/谷氨酸反向转运体System Xc<sup>-</sup>的核心亚基，可以调控GSH水平，进而影响细胞铁死亡<sup>［<xref ref-type="bibr" rid="R9">9</xref>］</sup>。<italic>SLC7A11</italic>通过维持GSH合成抑制铁死亡，而铁死亡在肿瘤发生中具有抑癌作用<sup>［<xref ref-type="bibr" rid="R10">10</xref>］</sup>。其异常直接影响了胃癌的发生发展。然而目前关于<italic>SLC7A11</italic>的SNP与<italic>H. pylori</italic>感染及NCGC发病风险的关联性还未见报道。因此本研究在包头汉族人群中探讨<italic>SLC7A11</italic>基因多态性与<italic>H. pylori</italic>感染及NCGC发病风险的关联性。</p><p>本研究结果显示，SNP rs7674870、rs11734488和rs12506138与<italic>H. pylori</italic>感染无显著关联（<italic>P</italic>&gt;0.05）。<italic>SLC7A11</italic> rs12506138在共显性、显性、隐性模型下均与NCGC相关联，其中共显性模型为最佳遗传模型。在共显性模型下，CC和CT基因型相比于TT基因型显著降低了NCGC发病风险。</p><p>NCBI网站显示rs12506138位于<italic>SLC7A11</italic>的5'上游区域，提示rs12506138可能通过影响<italic>SLC7A11</italic>的转录效率影响NCGC的发病风险。然而这一SNP如何影响转录调控以及与NCGC发病风险的关系还有待实验进一步验证。</p><p>rs7674870、rs11734488与<italic>H. pylori</italic>感染和NCGC发病均无关联，提示其在胃癌变过程中不起主要作用。rs12506138与<italic>H. pylori</italic>感染无关联，但与NCGC发病相关，提示其可能在NCGC癌变后期发生作用。</p><p>值得注意的是，由rs7674870、rs11734488、rs12506138构建的A-C-C单体型和A-T-C单体型显著降低NCGC发病风险，而A-T-T单体型和G-C-C单体型则增加NCGC发病风险，提示这三个SNP构成的单体型可能在NCGC发病中起到一定的作用。</p><p>本实验存在局限性，首先本研究样本均来自同一地区人群，其次样本量偏低，后续应在更广泛的地区扩大样本量进行研究，以确认这些SNP与<italic>H. pylori</italic>感染和NCGC发病风险的相关性，为NCGC易感人群的筛查提供实验基础。</p></sec></body><back><ref-list><title>参考文献</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Thrift</surname><given-names>A P</given-names></name>， <name name-style="eastern"><surname>Wenker</surname><given-names>T N</given-names></name>， <name name-style="eastern"><surname>El-Serag</surname><given-names>H B</given-names></name></person-group>. <article-title>Global burden of gastric cancer： epidemiological trends， risk factors， screening and prevention</article-title>［J］. <source>Nat Rev Clin Oncol</source>， <year>2023</year>， <volume>20</volume>（<issue>5</issue>）： <fpage>338</fpage>-<lpage>49</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41571-023-00747-0">10.1038/s41571-023-00747-0</ext-link></comment>.</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Zhang</surname><given-names>H L</given-names></name>， <name name-style="eastern"><surname>Guo</surname><given-names>Y Q</given-names></name>， <name name-style="eastern"><surname>Liu</surname><given-names>S</given-names></name>， <etal>et al</etal></person-group>. <article-title>Galectin-13 reduces membrane localization of SLC7A11 for ferroptosis propagation</article-title>［J］. <source>Nat Chem Biol</source>， <year>2025</year>， <volume>21</volume>（<issue>10</issue>）： <fpage>1531</fpage>-<lpage>43</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41589-025-01888-2">10.1038/s41589-025-01888-2</ext-link></comment>.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Koppula</surname><given-names>P</given-names></name>， <name name-style="eastern"><surname>Zhuang</surname><given-names>L</given-names></name>， <name name-style="eastern"><surname>Gan</surname><given-names>B</given-names></name></person-group>. <article-title>Cystine transporter SLC7A11/xCT in cancer： ferroptosis， nutrient dependency， and cancer therapy</article-title>［J］. <source>Protein Cell</source>， <year>2021</year>， <volume>12</volume>（<issue>8</issue>）： <fpage>599</fpage>-<lpage>620</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1007/s13238-020-00789-5">10.1007/s13238-020-00789-5</ext-link></comment>.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Yan</surname><given-names>Y</given-names></name>， <name name-style="eastern"><surname>Teng</surname><given-names>H</given-names></name>， <name name-style="eastern"><surname>Hang</surname><given-names>Q</given-names></name>， <etal>et al</etal></person-group>. <article-title>SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells</article-title>［J］. <source>Nat Commun</source>， <year>2023</year>， <volume>14</volume>（<issue>1</issue>）： <fpage>3673</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41467-023-39401-9">10.1038/s41467-023-39401-9</ext-link></comment>.</mixed-citation></ref><ref id="R5"><label>5</label><citation-alternatives><mixed-citation publication-type="journal" publication-format="print"><person-group><string-name>马立聪</string-name>， <string-name>田旭阳</string-name>， <string-name>王兴宇</string-name>， <etal>等</etal></person-group>. <article-title>YAP基因多态性与幽门螺杆菌感染及非贲门胃癌发病风险的关联性分析</article-title>［J］. <source>安徽医科大学学报</source>， <year>2021</year>， <volume>56</volume>（<issue>9</issue>）： <fpage>1500</fpage>-<lpage>4</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2021.09.029">10.19405/j.cnki.issn1000-1492.2021.09.029</ext-link></comment>.</mixed-citation><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Ma</surname><given-names>L C</given-names></name>， <name name-style="eastern"><surname>Tian</surname><given-names>X Y</given-names></name>， <name name-style="eastern"><surname>Wang</surname><given-names>X Y</given-names></name>， <etal>et al</etal></person-group>. <article-title>Association analysis of SNPs in YAP gene with the infection of <italic>Helicobacter</italic> <italic>pylori</italic> and non-cardia gastric cancer</article-title>［J］. <source>Acta Univ Med Anhui</source>， <year>2021</year>， <volume>56</volume>（<issue>9</issue>）： <fpage>1500</fpage>-<lpage>4</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2021.09.029">10.19405/j.cnki.issn1000-1492. 2021. 09.029</ext-link></comment>.</mixed-citation></citation-alternatives></ref><ref id="R6"><label>6</label><citation-alternatives><mixed-citation publication-type="journal" publication-format="print"><person-group><string-name>陈雅茹</string-name>， <string-name>高　芳</string-name>， <string-name>董文杰</string-name>， <etal>等</etal></person-group>. <article-title>GPX4基因多态性与非贲门胃癌的关系</article-title>［J］. <source>安徽医科大学学报</source>， <year>2025</year>， <volume>60</volume>（<issue>3</issue>）： <fpage>399</fpage>-<lpage>404</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2025.03.003">10.19405/j.cnki.issn1000-1492.2025.03.003</ext-link></comment>.</mixed-citation><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Chen</surname><given-names>Y R</given-names></name>， <name name-style="eastern"><surname>Gao</surname><given-names>F</given-names></name>， <name name-style="eastern"><surname>Dong</surname><given-names>W J</given-names></name>， <etal>et al</etal></person-group>. <article-title>Association of GPX4 gene polymorphisms with non-cardia gastric cancer</article-title>［J］. <source>Acta Univ Med Anhui</source>， <year>2025</year>， <volume>60</volume>（<issue>3</issue>）： <fpage>399</fpage>-<lpage>404</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2025.03.003">10.19405/j.cnki.issn1000-1492.2025.03.003</ext-link></comment>.</mixed-citation></citation-alternatives></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Yang</surname><given-names>L</given-names></name>， <name name-style="eastern"><surname>Kartsonaki</surname><given-names>C</given-names></name>， <name name-style="eastern"><surname>Yao</surname><given-names>P</given-names></name>， <etal>et al</etal></person-group>. <article-title>The relative and attributable risks of cardia and non-cardia gastric cancer associated with <italic>Helicobacter</italic> <italic>pylori</italic> infection in China： a case-cohort study</article-title>［J］. <source>Lancet Public Health</source>， <year>2021</year>， <volume>6</volume>（<issue>12</issue>）： <elocation-id>e888-96</elocation-id>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1016/S2468-2667（21）00164-X">10.1016/S2468-2667（21）00164-X</ext-link></comment>.</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Sun</surname><given-names>Q</given-names></name>， <name name-style="eastern"><surname>Yuan</surname><given-names>C</given-names></name>， <name name-style="eastern"><surname>Zhou</surname><given-names>S</given-names></name>， <etal>et al</etal></person-group>. <article-title><italic>Helicobacter pylori</italic> infection： a dynamic process from diagnosis to treatment</article-title>［J］. <source>Front Cell Infect Microbiol</source>， <year>2023</year>， <volume>13</volume>： <fpage>1257817</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3389/fcimb.2023.1257817">10.3389/fcimb. 2023. 1257817</ext-link></comment>.</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Zhang</surname><given-names>H</given-names></name>， <name name-style="eastern"><surname>Ma</surname><given-names>J</given-names></name>， <name name-style="eastern"><surname>Hou</surname><given-names>C</given-names></name>， <etal>et al</etal></person-group>. <article-title>A ROS-mediated oxidation-O-GlcNAcylation cascade governs ferroptosis</article-title>［J］. <source>Nat Cell Biol</source>， <year>2025</year>， <volume>27</volume>（<issue>8</issue>）： <fpage>1288</fpage>-<lpage>300</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41556-025-01722-w">10.1038/s41556-025-01722-w</ext-link></comment>.</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Jiang</surname><given-names>X</given-names></name>， <name name-style="eastern"><surname>Stockwell</surname><given-names>B R</given-names></name>， <name name-style="eastern"><surname>Conrad</surname><given-names>M</given-names></name></person-group>. <article-title>Ferroptosis： mechanisms， biology and role in disease</article-title>［J］. <source>Nat Rev Mol Cell Biol</source>， <year>2021</year>， <volume>22</volume>（<issue>4</issue>）： <fpage>266</fpage>-<lpage>82</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41580-020-00324-8">10.1038/s41580-020-00324-8</ext-link></comment>.</mixed-citation></ref></ref-list><fn-group><fn fn-type="other" specific-use="citation-format"><p>汪琳丽, 高芳, 董文杰, 等. <italic>SLC7A11</italic>基因多态性与幽门螺杆菌感染及非贲门胃癌的关联研究[J]. 安徽医科大学学报, 2026, 61(06): 1124-1129.</p></fn><fn fn-type="other" specific-use="citation-format" xml:lang="en"><p>Wang Linli, Gao Fang, Dong Wenjie, et al. Association study of <italic>SLC7A11</italic> gene polymorphisms with <italic>helicobacter pylori</italic> infection and non-cardia gastric cancer[J]. Acta Universitatis Medicinalis Anhui, 2026, 61(06): 1124-1129.</p></fn></fn-group></back><?original-text name="authorName-zh" content="汪琳丽<sup>1*</sup>，高  芳<sup>2*</sup>，董文杰<sup>1</sup>，褚  宁<sup>1</sup>，贾彦彬<sup>1</sup>"?><?original-text name="authorAff-zh" content="（包头医学院<sup>1</sup>基础医学与法医学院、<sup>2</sup>医学技术学院，包头  014040）"?><?original-text name="authorName-en" content="Wang Linli<sup>1</sup>， Gao Fang<sup>2</sup>， Dong Wenjie<sup>1</sup>， Chu Ning<sup>1</sup>， Jia Yanbin<sup>1</sup>"?><?original-text name="authorAff-en" content="（<sup>1</sup>School of Basic Medicine and Forensic Medicine， <sup>2</sup>School of Medical Technology， Baotou Medical College， Baotou  014040）"?></article>